Egetis Therapeutics (EGTX) Q3 2025 earnings summary

Executive summary

• FDA granted Breakthrough Therapy Designation for Emcitate® (tiratricol/Triac) in July 2025, supporting NDA submission for MCT8 deficiency based on robust clinical data, with rolling NDA to begin December 2025 and full submission in early 2026; FDA review completion is expected in Q3 2026 if Priority Review is granted.

• Positive results from the ReTRIACt/ReTRIEVE study support NDA submission and address regulatory feedback in France.

• Emcitate®/Triac approved and launched in Germany as the first and only treatment for MCT8 deficiency in the EU, with commercial expansion through partnerships in Turkey, the Gulf region, and Japan.

• U.S. commercialization infrastructure is being built, with expanded access programs at 15 sites and growing awareness among healthcare providers.

• Strategic partnerships and distribution agreements established for Japan, Türkiye, and the Gulf region.

Financial highlights

• Q3 2025 revenue was SEK 17.4 million (MSEK 17.4), up from SEK 9.4 million year-over-year; nine-month revenue reached SEK 44.6 million, up from SEK 35.3 million.

• Adjusted gross profit for nine months was SEK 35.3 million, with an improved margin of 79% versus 73% in 2024.

• Net loss after tax for nine months was SEK 222.8 million, improved from SEK 233.1 million; Q3 net loss was SEK 82.4 million, improved from SEK 86.2 million.

• Cash position at end of September 2025 was SEK 145.7 million, strengthened by a SEK 183 million rights issue post-period.

• Debt repayments of SEK 21.7 million reported for the first nine months.

Outlook and guidance

• Rolling NDA submission for Emcitate®/Triac in the U.S. to begin December 2025, with full submission in early 2026 and expected FDA review completion in Q3 2026.

• Commercialization in Europe continues, with pricing and reimbursement processes ongoing in France, Italy, and Spain; resubmission for reimbursement in France planned for early 2026.

• U.S. launch preparations include expanded access programs and market access readiness, targeting around 25 FTEs at launch.

• Key milestones for 2025-2026 include further EU launches, US NDA submission and approval, and potential initiation of new studies for RTH-beta.